Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

A new clinically proven and reliable medical solution for continuous heart arrhythmia and blood pressure monitoring

Project description

A comfortable watch that can also warn us of the risk of a heart attack or stroke

The EU-funded CARDIACSENSE project has developed a non-invasive wearable device for monitoring vital signs, such as blood pressure and heartbeat. The key objective is to detect atrial fibrillation (AF), the most common irregular heartbeat condition encountered in adults, as well as hypertension (HTN). The CARDIACSENSE provides real-time measuring, it is highly sensitive and easy to use and facilitates data storage and sharing. Uniquely, it incorporates an artefact sensor that detects finger and wrist movements, thereby avoiding false-positive results. Considering the EUR billions in healthcare costs, the CARDIACSENSE device has a real potential to reduce AF- and HTN-associated morbidities through the prompt diagnosis of the condition.

Objective

Atrial fibrillation (AF) is the most common heart arrhythmia in adults and a major risk factor for ischaemic stroke (increased by 500%), costing globally around €500Bn/year. On the other hand, Hypertension (HTN) is a condition, mostly encountered in patients suffering from AF, although only half of these individuals have this condition under control, and only 20% are unaware that they have HTN. Besides the health risks associated with these conditions, there is a lack of non-obtrusive, non-inflating, non-invasive, small, precise, easy-to-use devices for continuous monitoring of vital signs, including AF and blood pressure. Cardiac Sense Ltd is an Israeli start-up established in 2009, with a vision of developing innovative non-invasive technology for monitoring vital signs. We are developing CardiacSense (TRL6), a clinically-proven medical solution that reliably delivers non-invasive and non-inflating heart arrhythmia and blood pressure monitoring, 23/365 for as long as needed. It mainly consists of a wearable (a watch), highly sensitive, error-free (introducing an artefact sensor), real-time measuring device, that is non-invasive (no surgery needed), easy to use (no training needed) and allows for a great connectivity (providing easy data storage and sharing). Our solution is based on optical PPG sensor technology to monitor heart AF and BP. In addition, we are the first company to develop a unique artefact sensor that detects finger and wrist movements that affect the PPG signal by increasing false positive results. Our solution thus has a medical grade accuracy level of pulse measurement. Through this project we aim to finalize its development and launch it to the market, with a potential to save around €800M to EU healthcare and save up to 5,000 lives yearly, and to boost our company's growth to +€7.5M revenues, and +20 new jobs by 2025.

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-1 - SME instrument phase 1

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

CARDIACSENSE
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 50 000,00
Address
6 LESHEM ST
3079825 CAESARA
Israel

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 71 429,00
My booklet 0 0